Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ASCO GI 2023 | The future of targeted therapies for advanced colorectal cancer

Kristen Keon Ciombor, MD, Vanderbilt Health, Nashville, TN, provides an overview of advances in targeted therapies for advanced colorectal cancer. Current actionable targets include BRAF, HER2, RAS, and microsatellite instability (MSI) high, as well as rarer mutations such as NTRK. Recent studies have suggested moving targeted therapies to earlier lines of treatment, and the KEYNOTE-177 (NCT02563002) and CheckMate142 (NCT02060188) trials have demonstrated the utility of immunotherapy in the first-line setting for MSI-high colorectal cancer. This interview took place at the American Society of Clinical Oncology (ASCO) 2023 Gastrointestinal Cancers (GI) Symposium in San Francisco, CA.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

View our new feature exploring genomic biomarkers in metastatic colorectal cancer here: https://bit.ly/3DcSevZ